Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPensionProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fresenius Medical Care AG (FMS) Liabilities and Shareholders Equity (2016 - 2025)

Fresenius Medical Care AG (FMS) has 16 years of Liabilities and Shareholders Equity data on record, last reported at $36.1 billion in Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 0.61% year-over-year to $36.1 billion; the TTM value through Dec 2025 reached $72.1 billion, down 2.3%, while the annual FY2025 figure was $35.0 billion, 3.59% down from the prior year.
  • Liabilities and Shareholders Equity reached $36.1 billion in Q4 2025 per FMS's latest filing, up from $35.9 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $36.1 billion in Q4 2025 and bottomed at $43.7 million in Q4 2022.
  • Average Liabilities and Shareholders Equity over 4 years is $18.0 billion, with a median of $18.0 billion recorded in 2021.
  • Peak YoY movement for Liabilities and Shareholders Equity: tumbled 99.85% in 2021, then rose 0.61% in 2025.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $58.0 million in 2021, then decreased by 24.69% to $43.7 million in 2022, then surged by 82056.54% to $35.9 billion in 2024, then rose by 0.61% to $36.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $36.1 billion in Q4 2025, $35.9 billion in Q4 2024, and $43.7 million in Q4 2022.